AstraZeneca’s (AZN) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating restated by analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Tuesday, Digital Look reports. They currently have a £117 target price on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential downside of 6.01% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Berenberg Bank reduced their price target on AstraZeneca from £160 to £150 and set a “buy” rating on the stock in a research note on Tuesday, September 15th. Jefferies Financial Group reiterated a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Wednesday, September 9th. Citigroup increased their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a £145 target price on shares of AstraZeneca in a research report on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of £150.

AstraZeneca Stock Performance

AstraZeneca stock traded down GBX 44 during mid-day trading on Tuesday, reaching £124.48. The company’s stock had a trading volume of 27,813,750 shares, compared to its average volume of 30,410,363. AstraZeneca has a 12-month low of £109.22 and a 12-month high of £157.32. The firm’s fifty day moving average price is £121.73 and its two-hundred day moving average price is £133.31. The company has a debt-to-equity ratio of 64.10, a quick ratio of 0.59 and a current ratio of 0.89. The company has a market capitalization of £193.06 billion, a P/E ratio of 18.63, a PEG ratio of 0.86 and a beta of 0.20.

Insiders Place Their Bets

In related news, insider Michel Demare bought 2,500 shares of the stock in a transaction on Monday, September 14th. The shares were purchased at an average price of £121.21 per share, for a total transaction of £303,025. 0.15% of the stock is owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.